Integrating inflammation-based scores into gastric cancer prognosis

The conventional tumor-node-metastasis (TNM) staging system is crucial for predicting the prognosis of gastric cancer. However, TNM staging fails to delineate tumor biology and host immune responses. Zhou <i>et al</i> have addressed this in a noteworthy study, they analyzed a cohort of 1071 patients with stage I-III gastric cancer who had undergone radical gastrectomy. The systemic inflammation response index (SIRI) and platelet-to-lymphocyte ratio (PLR) score were derived from the SIRI and PLR. Multivariate analysis identified the SIRI-PLR score as an independent predictor of survival. This was significant along with factors such as age, tumor size, and TNM stage. Importantly, they created a nomogram that integrated these variables, demonstrating superior predictive accuracy compared to the TNM staging system. The findings of this single-center cohort study require prospective multicenter validation to confirm their reproducibility and generalizability. Furthermore, inflammatory markers are dynamic and serial measurements can offer a more refined assessment of patient prognoses and guide treatment responses. These findings should be combined with genomic, immunological, and radiomics data. This approach promises precise and personalized risk stratification, thereby improving the prediction of prognosis in patients with gastric cancer.